BioDuro Launches New Antibody & Cell Therapy Discovery Services

BioSpace | March 02, 2020

BioDuro LLC, a leading global life sciences contract research and development organization, announced today that it has broadly launched new antibody- and cell-based therapy discovery services. The services have already been validated by early-access partners that have advanced several biologics-based therapies into the clinic. The Biologics Discovery team at BioDuro has more than 40 scientists and is led by a pharma- and biotech-experienced team with more than 100 years of combined biologics experience. The new service offerings, focused on antibody discovery and cellular therapies, include:

Spotlight

GMOs, or more accurately called Genetic Engineering (GE), builds on traditional plant cross breeding by allowing a more precise way to identify and transfer selected genes from one plant to another to create a desired characteristic. It’s used to address agricultural challenges, and increasingly to provide direct consumer benefits.

Spotlight

GMOs, or more accurately called Genetic Engineering (GE), builds on traditional plant cross breeding by allowing a more precise way to identify and transfer selected genes from one plant to another to create a desired characteristic. It’s used to address agricultural challenges, and increasingly to provide direct consumer benefits.

Related News

MEDICAL

WuXi ATU and Wugen Announce Manufacturing Partnership to Expedite the Delivery of Novel Cell Cancer Immunotherapies

Wugen | June 16, 2022

WuXi Advanced Therapies (WuXi ATU), a global Contract Testing, Development and Manufacturing Organization (CTDMO), and Wugen Inc., a clinical-stage biotechnology company based in St. Louis and San Diego, today announced a partnership to produce Wugen's WU-NK-101, a novel immunotherapy that harnesses the power of memory natural killer (NK) cells to treat cancers. WuXi ATU will provide manufacturing and testing services for WU-NK-101 to enable the delivery of this innovative cell therapy product to cancer patients. Wugen aims to develop a pipeline of off-the-shelf cell therapy products to treat a broad range of hematological and solid tumor malignancies. As Wugen's first program from the company's proprietary MonetaTM platform, WU-NK-101 leverages the hyper-functional, long-lasting anti-tumor functionality of memory NK cells to manufacture next-generation, off-the-shelf cancer cell therapies at commercial scale. WU-NK-101 is currently in development to treat acute myelogenous leukemia (AML) and solid tumors. WuXi ATU's integrated CTDMO platform enables the development of WU-NK-101 by leveraging the company's Good Manufacturing Process (GMP) cell therapy manufacturing and testing capabilities to support regulatory filings and clinical trials. We are delighted to partner with WuXi ATU, With WuXi ATU's cell therapy manufacturing expertise, integrated GMP manufacturing and testing capabilities, we can keep advancing our allogeneic WU-NK-101 program into clinical trials and accelerate the timeline for delivering convenient, effective therapeutics to patients." Dr. Dan Kemp, President and Chief Executive Officer of Wugen. About WU-NK-101 WU-NK-101 is a novel immunotherapy harnessing the power of memory natural killer (NK) cells to treat liquid and solid tumors. Memory NK cells are hyper-functional, long-lasting immune cells that exhibit enhanced anti-tumor activity and a cytokine-induced memory-like (CIML) phenotype. This rare cell population has a superior phenotype, proliferation capacity, and metabolic fitness that makes it better suited for cancer therapy than other NK cell therapies. Wugen is applying its proprietary MonetaTM platform to advance WU-NK-101 as a commercially scalable, off-the-shelf cell therapy for cancer. WU-NK-101 is currently in development for acute myelogenous leukemia (AML) and solid tumors. About Wugen Wugen, Inc., is a clinical-stage biotechnology company developing the next generation of off-the-shelf memory natural killer (NK) and CAR-T cell therapies for cancer. Wugen is leveraging its proprietary MonetaTM platform and deep genomic engineering expertise to pioneer a new class of memory NK cell therapies with a cytokine-induced memory-like (CIML) phenotype, uniquely designed to treat hematological and solid tumor malignancies.

Read More

MEDTECH

Carl Zeiss Meditec and Precise Bio Announce Partnership in the Development and Commercialization of Tissue-Based Implants for Ophthalmology

Precise Bio | July 19, 2022

Carl Zeiss Meditec and Precise Bio, a regenerative medicine company advancing the use of bio-printed tissues and organs, announced today that the companies have entered into a partnership to develop and commercialize fabricated corneal tissue for transplants in patients that require endothelial keratoplasty and natural lenticule transplants for treating keratoconus and vision correction. Under the terms of the agreement, Carl Zeiss Meditec will invest in Precise Bio and fund the further development of Precise Bio's two cornea transplant products and has exclusive worldwide commercialization rights for these products. Financial terms were not disclosed. "This investment in Precise Bio is expected to complement our leading portfolio of cataract and corneal refractive workflow solutions. The technology has the potential to advance treatment options for corneal disease, as well as for elective procedures – furthering enabling optimization of patient care." Euan S. Thomson, PhD, President of Ophthalmic Devices and Head of the Digital Business Unit for Carl Zeiss Meditec "We are very excited with this partnership that builds on our successful, ongoing collaboration with ZEISS for the development of corneal tissues to address unmet needs in the field of ophthalmology," stated Aryeh Batt, Co- Founder and CEO of Precise Bio. "This strategic agreement leverages ZEISS' global leadership in ophthalmology and Precise' innovative and unique 4D bio-fabrication platform technology. We are confident that the synergy between the two companies will allow us to develop breakthrough solutions for recovering patients' eyesight, bringing hope to hundreds of millions of patients worldwide." Precise Bio combines engineering, biomaterials, cell technology, bioengineering, and 3D printing into an unparalleled 4D bio-fabrication platform for transplantable organs and tissues. The Company's proprietary platform technology allows to fabricate tissues by 'printing' cells in a single-cell resolution and spatial accuracy, enabling complex organoid constructs with both structural integrity and long-term cell viability. Overcoming multiple technology challenges, Precise Bio's 4D bio-fabrication technology allows to reliably scale up tissue engineering for clinical use, and produce large quantities in a reproducible, quality controlled and cost-effective process. Precise Bio's ophthalmological pipeline consists of three products, the two cornea products that are the subject of the collaboration with Carl Zeiss Meditec and a retinal implant for age-related macular degeneration, all of which demonstrated successful results in animal models. The Company's ophthalmological products address global markets exceeding $10 billion annually. Bio-fabricated tissues comprised of human cells and natural materials, mimicking the anatomical structure and natural tissue components, can replace damaged or diseased tissue, substitute for donor tissue in cases where there is lack of tissue or solve unmet therapeutic needs. About ZEISS Carl Zeiss Meditec AG AX and TecDAX of the German stock exchange, is one of the world's leading medical technology companies. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. The Company offers complete solutions, including implants and consumables, to diagnose and treat eye diseases. The Company creates innovative visualization solutions in the field of microsurgery. With approximately 3,531 employees worldwide, the Group generated revenue of €1,646.8m in fiscal year 2020/2. The Group's head office is located in Jena, Germany, and it has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Application and Research ore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the Company's presence in these rapidly developing economies. Around 41 percent of Carl Zeiss Meditec AG's shares are in free float. The remaining approx. 59 percent are held by Carl Zeiss AG, one of the world's leading groups in the optical and optoelectronic industries. About Precise Bio Precise Bio develops regenerative medicine therapies that can transform patient care across a wide range of medical indications. Precise Bio's proprietary, break-through 4D bio-fabricating platform overcomes limitations of existing extrusion and ink-jet printers and paves the way for fabricating clinically viable tissues and organs. The Company's initial product pipeline is focused on ophthalmology and includes fabricated functional corneal grafts, intrastromal lenticules for treating keratoconus and vision correction, and a retinal implant for age-related macular degeneration. The Company also has earlier R&D programs to address unmet needs in additional medical indications, which are limited by the number of available donor tissues and organs, or where today's critical health problems can be solved using Precise Bio's naturally-based, hyper-accurate technology.

Read More

MEDICAL

Invenshure Launches MEKanistic Therapeutics™

Invenshure | June 03, 2022

Venture studio Invenshure announces the launch of MEKanistic Therapeutics, a biotechnology company redefining precision oncology. Co-inventors and pioneers in the MEK inhibitor field, Judith Sebolt-Leopold, PhD, and Christopher Whitehead, PhD, MBA, have rationally designed a drug that blocks two, key pathways (EGFR and PI3K) used to signal cancer cell growth, with a single molecule. In preclinical studies, this first-in-class dual inhibitor shows unparalleled tumor shrinkage without the toxicity generally associated with current kinase inhibitors. MEKanistic is using cutting edge computational tools to not only understand how these pathways work, but also design medications that perfectly fit within those sites to inhibit the spread of cancer. We have two unique advantages. First, our lead drug's expanded therapeutic window means dramatically reduced side effects for cancer patients. Second, when it's paired with existing cancer therapies, our drug makes them much more effective, We are excited to partner with Pfizer Global R&D veterans, Drs. Leopold and Whitehead, to propel this important technology forward into clinical trials." Danny Cunagin, CEO of MEKanistic. MEKanistic will be launching a round of funding in the coming weeks to support the translation of our lead candidate (MTX-531) towards IND approval later this year with the anticipation of initiation of Phase 1 clinical trials in early 2023. MTX-531's initial application targets head and neck cancers with 900,000 cases worldwide per year. Ultimately, this drug has possible future applications for colon/rectal, esophageal, pancreatic, and some breast cancers. Our work could potentially impact millions of people each year." Chief Scientific Officer, Dr. Sebolt-Leopold. About Invenshure™ Invenshure is a venture studio that scours university research labs for novel and disruptive technologies ready for commercialization. Invenshure partners with top scientists, physicians, and researchers from the most trusted institutions in healthcare and technology. The company focuses on high-growth sectors including biotech, genomics, healthcare IT, diagnostics, cloud computing technologies, and wireless technologies.

Read More